Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs

References

• Groen RS, Gershenson DM, Fader AN. Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all. Gynecol Oncol. 2015 Feb;136(2):373–383. PubMed PMID: 25481800.
   PubMed Web of Science ®Google Scholar
• Harrison ML, Jameson C, Gore ME. Mucinous ovarian cancer. Int J Gynecol Cancer. 2008 Mar-Apr;18(2):209–214. PubMed PMID: 17624989.
   PubMed Web of Science ®Google Scholar
• Sung PL, Chang YH, Chao KC, et al. Global distribution pattern of histological subtypes of epithelial ovarian cancer: a database analysis and systematic review. Gynecol Oncol. 2014 May;133(2):147–154. PubMed PMID: 24556058.
   PubMed Web of Science ®Google Scholar
• Cheasley D, Wakefield MJ, Ryland GL, et al. The molecular origin and taxonomy of mucinous ovarian carcinoma. Nat Commun. 2019 Sep 2;10(1):3935. PubMed PMID: 31477716; PubMed Central PMCID: PMCPMC6718426.
   PubMedGoogle Scholar
• Bassiouny D, Ismiil N, Dube V, et al. Comprehensive clinicopathologic and updated immunohistochemical characterization of primary ovarian mucinous carcinoma. Int J Surg Pathol. 2018 Jun;26(4):306–317. PubMed PMID: 29338553.
   PubMed Web of Science ®Google Scholar
• Winter WE 3rd, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2007 Aug 20;25(24):3621–3627. PubMed PMID: 17704411.
   PubMed Web of Science ®Google Scholar
• Mackay HJ, Brady MF, Oza AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer. 2010 Aug;20(6):945–952. PubMed PMID: 20683400.
   PubMed Web of Science ®Google Scholar
• Alexandre J, Ray-Coquard I, Selle F, et al. Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. Ann Oncol. 2010 Dec;21(12):2377–2381. PubMed PMID: 20494964.
   PubMed Web of Science ®Google Scholar
• Simons M, Ezendam N, Bulten J, et al. Survival of patients with mucinous ovarian carcinoma and ovarian metastases: a population-based cancer registry study. Int J Gynecol Cancer. 2015 Sep;25(7):1208–1215. PubMed PMID: 25978291.
   PubMed Web of Science ®Google Scholar
• Karabuk E, Kose MF, Hizli D, et al. Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control study. J Gynecol Oncol. 2013 Apr;24(2):160–166. PubMed PMID: 23653834; PubMed Central PMCID: PMCPMC3644693.
   PubMed Web of Science ®Google Scholar
• Hess V, A’Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004 Mar 15;22(6):1040–1044. PubMed PMID: 15020606.
   PubMed Web of Science ®Google Scholar
• Pectasides D, Pectasides M, Farmakis D, et al. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. Gynecol Oncol. 2004 Oct;95(1):165–172. PubMed PMID: 15385127.
   PubMed Web of Science ®Google Scholar
• Pignata S, Ferrandina G, Scarfone G, et al. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer. 2008 Sep 1;8:252. PubMed PMID: 18761742; PubMed Central PMCID: PMCPMC2538544.
   PubMed Web of Science ®Google Scholar
• Kajiyama H, Mizuno M, Shibata K, et al. Extremely poor postrecurrence oncological outcome for patients with recurrent mucinous ovarian cancer. Int J Clin Oncol. 2014 Feb;19(1):121–126. PubMed PMID: 23392995.
   PubMed Web of Science ®Google Scholar
• Nasioudis D, Haggerty AF, Giuntoli RL 2nd, et al. Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma. Gynecol Oncol. 2019 Aug;154(2):302–307. PubMed PMID: 31155308.
   PubMed Web of Science ®Google Scholar
• Group TICONI. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360(9332):505–515.
   PubMed Web of Science ®Google Scholar
• Gore M, Hackshaw A, Brady WE, et al. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. Gynecol Oncol. 2019 Jun;153(3):541–548. PubMed PMID: 31005287; PubMed Central PMCID: PMCPMC6559214.
   PubMed Web of Science ®Google Scholar
• Jonckheere N, Skrypek N, Van Seuningen I. Mucins and tumor resistance to chemotherapeutic drugs. Biochim Biophys Acta. 2014 Aug;1846(1):142–151. PubMed PMID: 24785432.
   PubMed Web of Science ®Google Scholar
• Hugen N, Simons M, Halilovic A, et al. The molecular background of mucinous carcinoma beyond MUC2. J Pathol Clin Res. 2015 Jan;1(1):3–17. PubMed PMID: 27499889; PubMed Central PMCID: PMCPMC4858120.
   PubMedGoogle Scholar
• Geng F, Wang Z, Yin H, et al. Molecular targeted drugs and treatment of colorectal cancer: recent progress and future perspectives. Cancer Biother Radiopharm. 2017 Jun;32(5):149–160. PubMed PMID: 28622036.
   PubMed Web of Science ®Google Scholar
• Gemignani ML, Schlaerth AC, Bogomolniy F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol. 2003 Aug;90(2):378–381. PubMed PMID: 12893203.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Lee MY, Ruan A, et al. Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms. Oncotarget. 2016 Dec 13;7(50):82097–82103. PubMed PMID: 27888800; PubMed Central PMCID: PMCPMC5347677.
   PubMedGoogle Scholar
• Anglesio MS, Kommoss S, Tolcher MC, et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2013 Jan;229(1):111–120. PubMed PMID: 22899400.
   PubMed Web of Science ®Google Scholar
• Murugan AK, Grieco M, Tsuchida N. RAS mutations in human cancers: roles in precision medicine. Semin Cancer Biol. 2019. cited 2019 Jun 27. DOI:10.1016/j.semcancer.2019.06.007.
   Google Scholar
• Sato N, Saga Y, Mizukami H, et al. Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations. Oncol Rep. 2012 May;27(5):1336–1340. PubMed PMID: 22246397.
   PubMed Web of Science ®Google Scholar
• McAlpine JN, Wiegand KC, Vang R, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 2009 Dec 10;9:433. PubMed PMID: 20003286; PubMed Central PMCID: PMCPMC2803495.
   PubMed Web of Science ®Google Scholar
• Ryland GL, Hunter SM, Doyle MA, et al. Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Med. 2015;7(1):87. PubMed PMID: 26257827; PubMed Central PMCID: PMCPMC4528310.
   PubMedGoogle Scholar
• Xiao J, Xu M, Hou T, et al. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling. Mol Med Rep. 2015 Sep;12(3):3249–3256. PubMed PMID: 25975261; PubMed Central PMCID: PMCPMC4526065.
   PubMed Web of Science ®Google Scholar
• Liu T, Hu W, Dalton HJ, et al. Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res. 2013 Dec 1;19(23):6532–6543. 10.1158/1078-0432.CCR-13-1305. PubMed PMID: 24100628; PubMed Central PMCID: PMCPMC3852199.
   PubMed Web of Science ®Google Scholar
• Bai H, Li H, Li W, et al. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines. Oncotarget. 2015 Sep 22;6(28):25520–25532. PubMed PMID: 26267321; PubMed Central PMCID: PMCPMC4694849.
   PubMedGoogle Scholar
• Kudoh A, Oishi T, Itamochi H, et al. Dual inhibition of phosphatidylinositol 3ʹ-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary. Int J Gynecol Cancer. 2014 Mar;24(3):444–453. PubMed PMID: 24552895.
   PubMed Web of Science ®Google Scholar